Valuation: Santhera Pharmaceuticals Holding AG

Market Cap 233M 281M 247M 212M 398M 26.96B 401M 2.79B 1.08B 13.78B 1.06B 1.03B 44.27B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 261M 315M 276M 238M 445M 30.17B 448M 3.12B 1.21B 15.41B 1.18B 1.16B 49.53B EV / Sales 2026 *
2.75x
EV / Sales 2027 * 2.2x
Free-Float
81.6%
Yield 2026 *
-
Yield 2027 * -
1 day-14.88%
Current month-14.88%
1 month-14.88%
3 months-14.88%
6 months+0.97%
Current year+48.24%
1 month 19.79
Extreme 19.79
19.79
Current year 15.63
Extreme 15.63
23.25
1 year 12.28
Extreme 12.275
23.25
3 years 9.4
Extreme 9.4
23.25
5 years 6.8
Extreme 6.8
23.25
10 years 6.8
Extreme 6.8
810.5
Manager TitleAgeSince
Chief Executive Officer 50 15/07/2026
Director of Finance/CFO 51 24/02/2025
Chief Operating Officer 55 01/09/2022
Director TitleAgeSince
Chairman 64 30/06/2022
Director/Board Member 58 04/04/2017
Director/Board Member 47 27/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
-14.88%0.00% - - 281M
+0.54%+1.30%+89.38%+41.17% 367B
+0.78%+3.97%+26.64%-14.56% 66.89B
-1.15%+1.29%+54.44%+196.07% 12.93B
+0.24%+0.49%-1.78%-14.49% 7.54B
-1.30%-2.32%-25.22%-10.07% 4.38B
-1.33%-2.37%-35.40%+4.72% 4.07B
-4.23%+2.14%-28.86%-12.33% 3.02B
-1.46%+1.57%-9.29%+46.05% 2.48B
-2.18%-0.66%-20.69%-32.24% 1.91B
Average -2.50%+0.17%+5.47%+22.70% 52.25B
Weighted average by Cap. +0.43%+1.57%+74.16%+35.20%

Financials

2026 *2027 *
Net sales 94.7M 114M 100M 86.3M 162M 10.95B 163M 1.13B 439M 5.6B 429M 420M 17.98B 116M 139M 122M 105M 197M 13.36B 199M 1.38B 536M 6.83B 523M 512M 21.94B
Net income - -
Net Debt 27.7M 33.42M 29.33M 25.24M 47.25M 3.2B 47.59M 331M 128M 1.64B 125M 123M 5.26B 21.4M 25.82M 22.66M 19.5M 36.51M 2.47B 36.77M 256M 99.19M 1.26B 96.95M 94.85M 4.06B
Logo Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Employees
94
Date Price Change Volume
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
15.22CHF
Average target price
27.50CHF
Spread / Average Target
+80.68%

Quarterly revenue - Rate of surprise